Evidence map›Paper›PMID 42324342›Full record

ArticleAnnals of hematology2026

Phase I study of oral azacitidine plus salvage chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.

Brian Hess, Nina D Wagner-Johnston, Lindsey Hendrickson, James A Davis, Elizabeth Hill, Anshu Giri, Kent Armeson, Maria V Revuelta, Shanta Salzer, Robin Klingenberg and 1 more

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Brian HessHollings Cancer Center, The Medical University of South Carolina, Charleston, SC, USA. hessbr@musc.edu.
Nina D Wagner-JohnstonSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Lindsey HendricksonHollings Cancer Center, The Medical University of South Carolina, Charleston, SC, USA.
James A DavisHollings Cancer Center, The Medical University of South Carolina, Charleston, SC, USA.
Elizabeth HillHollings Cancer Center, The Medical University of South Carolina, Charleston, SC, USA.
Anshu GiriHollings Cancer Center, The Medical University of South Carolina, Charleston, SC, USA.
Kent ArmesonHollings Cancer Center, The Medical University of South Carolina, Charleston, SC, USA.
Maria V RevueltaLaura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York University, New York, NY, USA.
Shanta SalzerHollings Cancer Center, The Medical University of South Carolina, Charleston, SC, USA.
Robin KlingenbergHollings Cancer Center, The Medical University of South Carolina, Charleston, SC, USA.
Leandro CerchiettiLaura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York University, New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Salvage chemotherapy and autologous stem cell transplantation (ASCT) offer the opportunity to cure eligible patients with relapsed diffuse large B-cell lymphoma (DLBCL). Epigenetic alterations such as aberrant DNA methylation patterns have been linked to chemotherapy resistance in DLBCL. Oral Azacitadine (AZA) is a hypomethylating agent that inhibits DNA methyltransferase and has provided evidence of chemotherapy sensitization in DLBCL. In this phase I trial the safety and feasibility of two dose levels of AZA were investigated in combination with standard cytotoxic chemotherapy rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in relapsed DLBCL patients who were candidates for ASCT.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsAzacitidineLymphoma, Large B-Cell, DiffuseSalvage TherapyAdministration, OralAdultAgedCarboplatinEtoposideFemaleHumansIfosfamideMaleMiddle AgedRecurrenceRituximabAzacitidineCarboplatinEtoposideIfosfamideRituximabDlbclEpigeneticsLymphoma

Identifiers

PMID42324342
PMCPMC13538234

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.